Preparation method and application of African swine fever virus membrane protein E146L
By constructing a recombinant expression plasmid of the ASFV E146L protein and expressing it in BHK-21 or CHO cells, the problem of identifying the outer envelope protein of African swine fever virus was solved, enabling efficient preparation of vaccines and diagnostic reagents with good immunoprotective function and biosafety.
Patent Information
- Application Number
- CN202311107477.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-31
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-08-31
AI Technical Summary
Existing technologies make it difficult to effectively identify and utilize the outer membrane proteins of African swine fever virus, resulting in a lack of effective viral membrane proteins with immune protective functions for the preparation of vaccines and diagnostic reagents.
By constructing a recombinant expression plasmid containing the ASFV E146L protein gene, transfecting BHK-21 or CHO cells, screening cell clones with high antigen expression levels, and obtaining stably expressed E146L protein through affinity chromatography purification, the protein can be used to prepare African swine fever virus vaccines and diagnostic reagents.
The ASFV E146L protein was expressed efficiently. The recombinant cell line has good antigenicity and immunogenicity, can induce high-titer virus-neutralizing antibodies, provide long-lasting immune protection, and the prepared vaccine is non-pathogenic and has high biosafety.
Smart Images

Figure CN117007801B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the preparation method and application of African swine fever virus membrane protein E146L, belonging to the field of animal vaccines and veterinary biological products technology. Background Technology
[0002] African swine fever (ASF) is an acute, febrile, and highly lethal infectious disease of pigs caused by the African swine fever virus (ASFV). ASFV primarily infects various breeds of domestic pigs, as well as African and Eurasian wild boars. Warthogs and bush pigs can also be infected but do not show clinical symptoms. Warthogs and other African wild boars, along with ticks, are hosts for ASFV. Infected domestic pigs typically exhibit symptoms such as high fever, severe depression, anorexia, cyanosis, systemic hemorrhagic lesions, respiratory distress, and neurological symptoms. The disease course is short, with a high mortality rate; the mortality rate in the most acute and acute forms can reach 100%. The World Organisation for Animal Health (OIE) lists it as a notifiable animal disease, and it is a key animal disease for prevention and control in my country. African swine fever poses a serious threat to the global pig industry. Since there is currently no universally recognized and effective commercially available vaccine for this disease, it is urgent to conduct research on the immunological function of important antigenic proteins of the pathogen and to identify important antigenic proteins in the African swine fever virus in order to promote research on disease control technologies.
[0003] ASFV belongs to the genus *Asfivirus* of the family *Asfarviridae*, and is the only member of this family. The ASFV virus particle is icosahedral in shape, approximately 200 nm in diameter, and has a double-membrane structure consisting of an inner membrane and an envelope. The virus replicates within the cytoplasm. The viral genome is a linear, covalently closed double-stranded DNA (dsDNA) molecule. The genome specificity and length of ASFV isolates vary across different regions, ranging from approximately 170 to 190 kb. Based on the characteristics of the p72 gene sequence, ASFV can be classified into 24 genotypes; the ASFV strain currently circulating in my country is genotype II. ASFV contains 151–167 open reading frames (ORFs); however, the functions of most proteins encoded by the viral genome remain unknown. The ASFV virus particle consists of a central nucleus, nucleocapsid, inner membrane, and icosahedral capsid. The virus acquires its outer envelope structure through budding from the cytoplasmic membrane. Of the more than 60 proteins that make up viral particles, they can be categorized by function into structural proteins and enzymes required for gene transcription and RNA processing. Within the viral particle structure, structural proteins in the outer envelope, capsid, and inner membrane may participate in the interaction between the virus and the host, as well as inducing the host's immune response. The structure and function of proteins in these regions are crucial for research on viral control technologies. Currently, only CD2v has been identified as a structural protein in the viral outer envelope; other proteins remain to be identified.
[0004] Among the membrane proteins encoded by the genome, most of the proteins found in the mass spectrometry identification of ASFV viral particles are inner membrane proteins. The reason why only a very small number of outer envelope proteins are found through mass spectrometry identification may be due to the large size of the virus and the instability of the outer envelope during viral particle purification, leading to the loss of outer envelope proteins. Therefore, identifying as many immune-protective viral membrane proteins as possible is extremely important for ASF prevention and control research. Summary of the Invention
[0005] To obtain more viral membrane proteins with immune protective functions and use them in the preparation of vaccines or diagnostic reagents for preventing African swine fever virus, the present invention provides the following technical solution:
[0006] This invention provides the application of African swine fever virus membrane protein E146L in the preparation of antigen reagents and kits for the diagnosis of African swine fever virus, the amino acid sequence of which is shown in SEQ ID NO.1.
[0007] This invention also provides the application of African swine fever virus membrane protein E146L in the preparation of positive serum detection reagents and kits for African swine fever virus diagnosis, wherein the amino acid sequence of African swine fever virus membrane protein E146L is shown in SEQ ID NO.1.
[0008] The present invention also provides the application of African swine fever virus membrane protein E146L in the preparation of a vaccine drug for the prevention of African swine fever virus, wherein the amino acid sequence of the African swine fever virus membrane protein E146L is shown in SEQ ID NO.1.
[0009] To further specify, the vaccine drug is an African swine fever subunit vaccine.
[0010] This invention also provides the application of a recombinant expression plasmid containing the gene expressing the African swine fever virus membrane protein E146L in the preparation of antigen reagents and kits for African swine fever virus diagnosis, or positive serum detection reagents and kits for African swine fever virus diagnosis, wherein the nucleotide sequence of the gene expressing the African swine fever virus membrane protein E146L is shown in SEQ ID NO.2.
[0011] The present invention also provides the application of a recombinant expression plasmid containing the gene expressing the African swine fever virus membrane protein E146L in the preparation of a vaccine drug for the prevention of African swine fever virus, wherein the nucleotide sequence of the gene expressing the African swine fever virus membrane protein E146L is shown in SEQ ID NO.2.
[0012] The present invention also provides a method for preparing African swine fever virus membrane protein E146L, the method comprising the following steps:
[0013] (1) Construct a recombinant expression plasmid containing the gene expressing the African swine fever virus membrane protein E146L; the nucleotide sequence of the gene expressing the African swine fever virus membrane protein E146L is shown in SEQ ID NO.2;
[0014] (2) Transfect BHK-21 cells or CHK-k1 cells with the recombinant expression plasmid obtained in step (1), and screen cell clones with strong IFA signal and high antigen expression by IFA identification.
[0015] (3) The cell clones obtained in step (2) are cultured, the cell supernatant is harvested, and after filtration and clarification, it is purified by affinity chromatography using Ni-NTA resin.
[0016] In one embodiment of the present invention, the construction method in step (1) is to clone the gene expressing African swine fever virus membrane protein E146L into the pUC57 plasmid; the eukaryotic expression vector pCAG-neo is treated with SacI and XhoI double enzyme digestion, and then ligated with the gene expressing African swine fever virus membrane protein E146L recovered by SacI and XhoI double enzyme digestion under the action of T4 DNA ligase; after transformation of DH5α competent cells, it is plated on LB plates containing ampicillin, cultured overnight, and single colonies are picked for amplification culture and plasmid is extracted.
[0017] In one embodiment of the present invention, the specific method of step (2) is to transfect BHK-21 cells or CHK-k1 cells with the recombinant expression plasmid obtained in step (1), add selective medium containing 100 μg / mL G418 for pressure culture after 48 h of transfection, digest the cells with trypsin after 4 days, passage them in 96-well plates by limiting dilution and continue to culture after 5 days, observe the number of cell clones in each well under an inverted microscope, select wells containing one cell colony and expand the culture in 24-well plates, 6-well plates and cell culture flasks, and at the same time perform IFA identification on each cell to screen cell clones with strong IFA signal and high antigen expression.
[0018] In one embodiment of the present invention, the culture method in step (3) is to culture and expand the cell clones obtained in step (2) in DMEM culture medium containing 10% fetal bovine serum, and then culture them in serum-free BHK cell culture medium for 3 days.
[0019] The beneficial effects of this invention are:
[0020] To identify more viral membrane proteins with immunoprotective functions, this invention previously conducted sequence analysis of the proteome encoding the ASFV Pig / HLJ / 18 strain genome. The analysis revealed that among the 163 encoded proteins longer than 60 amino acid residues, 35 contained transmembrane domains. This invention constructed eukaryotic expression plasmids for various membrane proteins, and after transfection into cells, immunological detection and analysis showed that the ASFV E146L protein possesses good antigenicity and immunogenicity. Therefore, this invention explores the use of the ASFV E146L protein in the preparation of vaccines and diagnostic reagents for the prevention of African swine fever virus.
[0021] This invention constructs a recombinant expression plasmid containing the gene expressing the E146L protein. Using this plasmid, BHK-21 cells or CHO cells are transfected to obtain a recombinant cell line stably expressing the E146L protein. This recombinant cell line or its culture can be used to prepare vaccines or drugs for the prevention of African swine fever virus disease or diagnostic reagents for African swine fever virus. The specific beneficial effects of this invention are as follows:
[0022] 1. The expression system selected in this invention is BHK-21 cells or CHO cells. The resulting recombinant cell line has biological characteristics similar to the parent cells, which is beneficial for the large-scale production of antigen proteins. The recombinant cell line has a high amount of antigenic epitopes, and the expressed protein can obtain a conformation and modification close to the natural conformation of viral proteins in the expression cells, resulting in good antigenicity. The recombinant cells can be cultured in suspension and fermented at high density, making it easy to produce in large quantities.
[0023] 2. The recombinant cell line of the present invention can be cultured and expressed using serum-free or low-serum culture medium, which can reduce the production cost of antigens or vaccines.
[0024] 3. This invention optimizes the gene codons of the antigen protein gene, which is beneficial to improving the antigen expression level.
[0025] 4. The oil adjuvant vaccine prepared using the recombinant expression cell line culture of the present invention can induce animals to produce high-titer virus-neutralizing antibodies with long duration of action, providing long-lasting and effective immune protection to immunized animals.
[0026] 5. The swine fever vaccine prepared by this invention does not contain viral nucleic acid, cannot replicate, is non-pathogenic, has extremely high biosafety, and the vaccine immunization is not affected by maternal antibodies or existing antibodies. Attached Figure Description
[0027] Figure 1 Figure 1 shows the results of Western blot analysis of cells transfected with African swine fever membrane protein expression plasmid.
[0028] Figure 2Figure showing the results of Western blot recognition of E146L protein in African swine fever-positive serum;
[0029] Figure 3 The image shows the results of Western blot identification of cell clones expressing E146L protein; among them, Figure 3 M stands for Marker. Figure 3 The numbers 1 through 10 correspond to clones 1 through 10, respectively.
[0030] Figure 4 Immunofluorescence identification results of cell lines expressing E146L protein;
[0031] Figure 5 The image shows the IFA detection results for stably transfected CHO cells; among them, Figure 5 In this context, A represents stably transfected CHO cells. Figure 5 In this context, B represents untransfected CHO cells;
[0032] Figure 6 Electrophoretic analysis results for purifying cell lines expressing E146L protein;
[0033] Figure 7 This is a graph showing the results of indirect ELISA detection of African swine fever virus antibodies. Detailed Implementation
[0034] The present invention will be further described in detail below with reference to specific embodiments and accompanying drawings. These embodiments are merely illustrative and not intended to limit the scope of the invention. Those skilled in the art should understand that modifications or substitutions can be made to the details and form of the technical solutions of the present invention without departing from the spirit and scope thereof, but such modifications and substitutions are all within the protection scope of the present invention. The processes, conditions, experimental methods, and reagents used in implementing the present invention, except as specifically mentioned below, are all common knowledge in the art and conventional market products; the present invention does not have any particular limitations.
[0035] The eukaryotic expression vector plasmid pCAG-neo, DH5α competent cells, and BHK-21 cells used in this invention were preserved by the State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.
[0036] The plasmid extraction kit and viral genome extraction kit are products of QIAGE.
[0037] The DNA gel recovery kit was purchased from Shanghai Huashun Biotechnology Co., Ltd.
[0038] G418 was purchased from Gibco.
[0039] The pancreatic enzyme was purchased from Hyclone.
[0040] Reverse Transcriptase M-MLV﹑PrimeSTAR TM HSDNA Polymerase﹑SalI﹑XhoI﹑
[0041] BamHI and T4 DNA ligase were purchased from Takara Bio Engineering (Dalian) Co., Ltd.
[0042] The anti-His-tagged monoclonal antibody was purchased from GeneTex.
[0043] FITC-labeled goat anti-mouse IgG was purchased from Zhongshan Jinqiao Biotechnology Co., Ltd.
[0044] Far-infrared fluorescently labeled goat anti-mouse IgG was purchased from LI-COR.
[0045] The HD Transfection Reagent transfection kit was purchased from Roche.
[0046] Example 1: Antigenicity analysis of African swine fever virus membrane protein E146L
[0047] Bioinformatics Analysis and Screening of Membrane Protein Genes: Identifying and screening protein antigens with good antigenicity is a crucial foundation for the development of African swine fever (ASF) vaccines. To screen for novel membrane protein antigens with good antigenicity for ASF virus, this invention used the genome sequence of the Chinese isolate Pig / HLJ / 18 as the analysis object, performing bioinformatics analysis on protein sequences encoding lengths greater than 60 amino acid residues. The results showed that the ASFV Pig / HLJ / 18 genome encoded 163 proteins with lengths greater than 60 amino acid residues. Among these 163 proteins, 35 contained transmembrane domains. Of these 35 membrane proteins, one (CD2v) was identified as an outer membrane protein, eight as inner membrane proteins, eight as viral structural proteins identified by mass spectrometry but with unclear locations, and 18 as unidentified transmembrane proteins with unclear locations. This bioinformatics analysis refined the target proteins for this project. Based on the bioinformatics analysis results, the target proteins for this project mainly selected non-inner membrane proteins with outer membrane domains longer than 100 amino acid residues. As a result, 12 membrane proteins were screened out for analysis and research. Detailed information is shown in Table 1.
[0048] Table 1 Information on the screening of ASFV-encoded membrane proteins
[0049]
[0050] Construction of membrane protein gene expression plasmids: First, the synthetic DNA sequence encoding the His tag sequence SEQ ID NO.3 (ggcggcggcagcggcggcggcagccaccaccaccaccaccacggcggcagcggcggccaccaccaccaccactaa) was inserted between the XhoI and BglII sites of plasmid pCAG-neo to construct the pCAGneo-His expression plasmid. Then, the gene sequence encoding the extramembrane domain of the selected target protein was synthesized and cloned into the SacI and XhoI sites of the expression plasmid pCAGneo-His to construct the membrane protein expression plasmid. After sequencing verification, the plasmid was extracted and prepared using a kit for cell transfection.
[0051] Transient expression and antigenicity detection of membrane proteins: Well-grown BHK-21 cells were digested and passaged into 24-well plates. When the BHK-21 cells reached 90% confluence, the expression was determined according to... HD Transfection Reagent Kit Instructions: Transfect cells using the recombinant plasmids. After 48 hours of transfection, remove the cell culture medium, wash cells once with PBS, add 200 μl of cell lysis buffer per well, covering the entire bottom of the well, and incubate at 4°C for 30 minutes for lysis. Collect the cell lysis buffer, centrifuge at 10,000 rpm for 10 minutes, and use the supernatant for electrophoresis. After electrophoresis, transfer the proteins to an NC membrane for Western blot analysis using anti-His tag protein antibody and ASFV-positive porcine serum as primary antibodies, respectively. Analysis with anti-His antibody showed that all 12 constructed membrane protein plasmids were expressed. Figure 1 Western blot analysis of membrane proteins using ASFV-positive porcine serum as the primary antibody showed that among all 12 membrane proteins, E146L protein exhibited a strong reaction signal with ASFV-positive serum, indicating that E146L protein possesses good antigenicity. Figure 2 ).
[0052] Example 2: Construction and detection of recombinant BHK cell lines stably expressing African swine fever virus membrane protein E146L
[0053] (1) Construction of recombinant expression plasmids
[0054] The opti-MGF110-13L gene is a gene encoding the extracellular region (30-146AA) of the ASFV E146L protein, optimized using eukaryotic codon bias. The amino acid sequence of the ASFV E146L protein is based on the protein sequence of ASFV HLJ / 18 strain (GenBank: QBH90616), retaining amino acids 30 to 146, and removing the N-terminal transmembrane sequence and the foreground sequence. The resulting amino acid sequence of the E146L protein is shown in SEQ ID NO.1. In designing this gene, a SacI restriction site, protective bases, and a Kozak sequence were added before the start codon; the start codon sequence and the DNA sequence encoding the signal peptide were added after the Kozak sequence; and an XhoI restriction site and protective bases were added to the coding end of the E146L protein gene. The opti-E146L gene and its specific amplification primers were synthesized by Nanjing Genscript Biotech Co., Ltd. The synthesized gene sequence is shown in SEQ ID NO.2, and the synthesized gene was cloned into the pUC57 plasmid. The eukaryotic expression vector pCAG-neo was double-digested with SacI and XhoI, and then ligated with the opti-E146L gene recovered after double digestion with SacI and XhoI using T4 DNA ligase. After transformation into DH5α competent cells, the cells were plated on LB agar plates containing ampicillin and cultured overnight. Single colonies were picked, amplified, and the plasmid was extracted. The plasmid was identified by double digestion with SacI and XhoI. The synthesized DNA sequence encoding the His tag sequence, SEQ ID NO.3 (ggcggcggcagcggcggcggcagccaccaccaccaccaccacggcggcagcggcggccaccaccaccaccactaa), was then inserted between the XhoI and BglII sites of the plasmid. The plasmid identified by enzyme digestion was named pCAGneo-opti-E146L and sent to a biotechnology company for sequencing verification. After sequencing verification, the plasmid was extracted and stored at -70℃ for later use.
[0055] SEQ ID NO.1:
[0056] GWSPFKYSKGNTVTFKTPDESSIAYMRFRNCVFTFTDPKGSLHSIDVTEVLNNMAKGFRDAQNPPSSFTLGGHCQAPLNAFSFVLPGVNDRATVATADEAKKWENCDATLTGLQRII
[0057] SEQ ID NO.2:
[0058] Atgaagttctcctgggtgatgttcttcctgatggccgtggtgaccggcgtgaactccggctggtcccccttcaagtactccaagggcaacaccgtgaccttc aagacccccgacgagtcctccatcgcctacatgcgcttccgcaactgcgtgttcaccttcaccgaccccaagggctccctgcactccatcgacgtgaccgag gtgctgaacaacatggccaagggcttccgcgacgcccagaaccccctcctccttcaccctgggcggccactgccaggcccccctgaacgccttctccttc gtgctgcccggcgtgaacgaccgcgccaccgtggccaccgccgacgaggccaagaagtgggagaactgcgacgccaccctgaccggcctgcagcgcatcatc
[0059] The recombinant expression plasmid pCAGneo-opti-E146L was digested with XhoI and SacI, and agarose gel electrophoresis analysis revealed two bands. The band pattern of the digestion product was consistent with the expected result. Meanwhile, sequencing results showed that the sequence between the SacI and XhoI restriction sites in the recombinant plasmid was completely consistent with the designed gene encoding the E146L protein.
[0060] (2) Cell transfection and screening
[0061] Select healthy BHK-21 cells, digest and passage them into 24-well plates. When the BHK-21 cells reach 90% confluence, proceed as follows: HD Transfection Reagent Kit Instructions: Transfect cells with recombinant plasmid pCAGneo-opti-E146L. 48 h after transfection, add selective medium containing G418 (100 μg / mL) and culture under pressure. After 4 days, trypsinize the cells and passage them in 96-well plates using limiting dilution. After 7 days, observe the number of cell colonies in each well under an inverted microscope. Select wells containing one cell colony (i.e., one cell clump) and subsequently expand the culture in 24-well plates, 6-well plates, and cell culture flasks. Simultaneously, perform IFA (Infectious Facial Expression) identification on each cell. Screen cell clones with strong IFA signals and high antigen expression levels.
[0062] In this invention, cells were transfected with recombinant plasmid pCAGneo-opti-E146L for 48 hours, then G418 selective medium was added, and the cells were passaged in 96-well plates using the limiting dilution method for further culture. After 7 days, clones containing single cell colonies were selected under an inverted microscope and identified by IFA, resulting in 10 positive cell clones.
[0063] (3) Western blot detection of E146L protein expression in clonal cells
[0064] After culturing the 10 positive cell clones in 24-well plates for 48 hours, the supernatant was collected. Using the culture supernatant of untransfected BHK-21 cells as a control, the supernatant was concentrated using ultrafiltration tubes and added to protein electrophoresis loading buffer. SDS-PAGE was performed using a 4-20% electrophoresis gel, and the samples were transferred to NC membranes. After blocking with 4% skim milk, a 1:500 dilution of anti-6×His-tagged monoclonal antibody was added, and the membranes were incubated at 37°C for 1 hour. After washing three times with PBST, the membranes were incubated at 37°C for 1 hour with a 1:10000 dilution of far-infrared fluorescently labeled goat anti-mouse IgG as a secondary antibody. After washing four times with PBST, the membranes were scanned using an infrared fluorescence imaging scanner. The relative expression levels of E146L protein were analyzed and compared, and the relative quantification of antigens expressed by each cell clone was used for screening.
[0065] This invention performed Western blot analysis on the culture supernatant of 10 positive clone cells. The results showed that clone 9 had the highest expression level among the 10 clone cells obtained. Figure 3 Therefore, clone 9 was retained for further analysis and for the expression, purification and preparation of E146L protein.
[0066] (4) Indirect immunofluorescence assay to detect the expression of the target protein in transfected cells.
[0067] Clones of 9 were seeded into 24-well or 12-well plates. After 24 hours, the culture medium was removed, and the cells were washed three times with PBS, fixed with 4% paraformaldehyde for 10 minutes, washed three times with PBS, treated with PBS containing 0.1% Triton X-100 for 10 minutes, washed three times with PBS, blocked with PBS containing 4% BSA for 2 hours, washed once with PBS, and then incubated overnight at 4°C with 1:500 diluted anti-6×His-tagged monoclonal antibody. The cells were washed three times with PBS, and then incubated at room temperature for 2 hours with FITC-labeled goat anti-mouse IgG diluted 1:200. The cells were washed three times with PBS, and the cell nuclei were then traced with DAPI. The results were observed under a fluorescence microscope.
[0068] Indirect immunofluorescence assays were performed on clone 9, which showed relatively high expression levels. The results indicated that this cell clone exhibited a strong yellow-green fluorescence signal and a high positive cell rate, with 100% positive cells within the visible field of view. Figure 4 The result indicates that the constructed and screened cell lines expressed stable values.
[0069] Example 3: Construction of a recombinant CHO cell line stably expressing African swine fever virus membrane protein E146L
[0070] The plasmids and cell transfection screening methods used to construct a stable recombinant CHO cell line expressing E146L protein were the same as in Example 2. The difference was that CHK-k1 cells were used. The specific steps were as follows: Selected CHK-k1 cells in good growth condition were digested and passaged into 24-well plates. When the CHK-k1 cells reached 90% confluence, they were then... HDTransfection Reagent Transfection Kit Instructions: Transfect cells with recombinant plasmid pCAGneo-opti-E146L. 48 h after transfection, add selective medium containing G418 (200 μg / mL) and culture under pressure. After 4 days, trypsinize the cells and passage them in 96-well plates using limiting dilution. After 7 days, observe the number of cell colonies in each well under an inverted microscope. Select wells containing one cell colony (i.e., one cell clump) and subsequently expand the culture in 24-well plates, 6-well plates, and cell culture flasks, while simultaneously performing IFA (Intracytoplasmic Saturation) identification on each cell. Cell clones with strong IFA signals and high antigen expression levels are selected for further amplification and protein expression. IFA identification results for stably transfected cell lines are shown below. Figure 5 As shown.
[0071] Example 4: Purification of E146L protein expressed in cell lines
[0072] The E146L protein stably expressing cell line obtained in Example 2 was cultured and expanded in DMEM medium containing 10% fetal bovine serum. After the cells expanded to a certain number, they were replaced with a maintenance expression medium—BHK cell serum-free medium. After culturing for 3 days, the cell culture supernatant was harvested. The supernatant was filtered and clarified, then purified by affinity chromatography using Ni-NTA resin. The purified E146L protein was subjected to SDS-PAGE electrophoresis, and the analysis showed that the purified recombinant protein E146L was obtained. Figure 6 The method for purifying recombinant protein E146L using the stable E146L protein expression cell line obtained in Example 3 is the same as above.
[0073] Example 5: Immunization test of pigs with cell line expressing recombinant protein E146L
[0074] Vaccine preparation: The BE146L protein purified in Example 4 was adjusted to a concentration of 125 μg / mL with PBS, and thimerosal was added to a final concentration of 0.02% to prepare the vaccine antigen solution. The vaccine antigen solution was mixed with MONTANIDE ISA 61VG adjuvant at a mass ratio of 4:6 and thoroughly emulsified to prepare a water-in-oil vaccine. The prepared vaccine was stored at 4°C for later use.
[0075] Animal grouping and immunization: Ten weaned Landrace piglets of similar age were randomly divided into two groups: Group 1 (n=5 pigs) served as the vaccine control group, immunized with 1 mL of E146L protein vaccine per pig; Group 2 (n=5 pigs) served as the control group, receiving 1 mL of PBS as a control at the same time as Group 1. A booster immunization was administered four weeks after the first immunization using the same dose and method. Serum samples were collected from the experimental pigs before immunization and at 14, 28, and 42 days post-immunization for E146L protein-specific antibody detection.
[0076] The method for detecting E146L protein-specific antibodies involves using indirect ELISA to detect E146L-specific antibodies in porcine serum collected before and after immunization. The specific method is as follows: ELISA plates are coated with 2 μg / mL purified E146L protein (100 μL / well), incubated overnight at 4°C, and then washed once with PBST. Blocking buffer containing 1% BSA is added, and the plates are blocked overnight at 4°C. The plates are then washed three times with PBST for 5 min each time. The porcine serum is then serially analyzed from 100x to 2x. Dilute the serum and add it to each ELISA plate. Incubate at 37°C for 1 hour, then wash with PBST 5 times for 5 minutes each time. Add 100 μL of HRP-labeled goat anti-pig IgG diluted 1:10000 to each well and incubate at 37°C for 30 minutes. Wash with PBST 5 times for 2 minutes each time. Add 100 μL of TMB chromogenic solution to each well and incubate at room temperature for 10 minutes. Add stop solution to terminate the chromogenic reaction and measure the absorbance at 450 nm using a multi-mode microplate reader.
[0077] Indirect ELISA antibody detection results showed that specific antibodies were induced in pigs immunized with the recombinant protein E146L vaccine two weeks later, with antibody levels gradually increasing and peaking at week 6 post-immunization. Control group pigs, however, remained E146L protein antibody negative throughout the experiment (Table 2).
[0078] Table 2. Results of antibody detection in porcine serum immunized with recombinant E146L protein.
[0079]
[0080] a The maximum serum dilution factor that yields a positive ELISA test is the ELISA antibody titer.
[0081] Example 6: Detection of African swine fever virus antibodies using indirect ELISA with recombinant cell line antigen expression.
[0082] The E146L protein purified in Example 4 was used as the coating antigen to coat 96-well polystyrene microplates. The antigen was diluted to a final concentration of 2 μg / mL with 0.1M carbonate buffer (pH 9.6), and 100 μL was added to each well of the plate. The plate was incubated overnight at 4°C. The plate was then washed three times with PBST (PBS + 0.05% Tween). The plate was blocked with PBST containing 1% BSA at 37°C for 2 hours. After blocking, the plate was washed three times with PBST and used immediately for detection or stored at -20°C for later use.
[0083] Antibody detection procedure: Add the porcine serum to be tested (qualitative test serum diluted 100-fold, antibody titer test serum serially diluted, and positive serum control, negative serum control, and blank control without serum added), incubate at 37℃ for 1 hour, wash 3 times with PBST buffer for 3 minutes each time; add horseradish peroxidase-labeled goat anti-pig IgG (Goat-anti-pig IgG-HRP), incubate at 37℃ for 1 hour, wash 4 times with PBST buffer for 3 minutes each time; add HRP chromogenic substrate (TMB chromogenic agent), incubate at room temperature for 5-15 minutes and observe the colorimetric reaction; after sufficient color development, add 2M sulfuric acid to terminate the colorimetric reaction; measure the absorbance at 450nm wavelength using an ELISA reader; determine the result.
[0084] When determining the results: the absorbance values of the blank control and negative serum wells are less than or equal to 0.2, and the absorbance value of the positive serum control wells is greater than 0.4. The P / N value is calculated as (OD value of the detection well - OD value of the blank control well) / (OD value of the negative serum - OD value of the blank control well). A P / N value equal to or greater than 2 is considered positive. The antibody titer of the sample serum is the maximum dilution factor of the positive serum.
[0085] Ten samples each of known swine fever virus antibody-positive and antibody-negative swine serum were selected and subjected to indirect ELISA detection using purified E146L protein as the coating antigen to assess the antigen's detection efficacy. The results are as follows: Figure 7 As shown, the OD450 values of all positive sera were greater than 0.6, and the OD450 values of all negative sera were less than 0.3. This indicates that the antigen has good specificity and sensitivity.
[0086] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be defined by the claims.
Claims
1. The application of African swine fever virus membrane protein E146L in the preparation of diagnostic antigen reagents and kits for African swine fever virus, characterized in that, The African swine fever virus membrane protein E146L is a protein composed of amino acid residues from position 30 to 146 of the E146L protein of the Pig / HLJ / 18 strain of African swine fever virus, and its amino acid sequence is shown in SEQ ID NO.1; the diagnostic antigen reagent and kit are used to detect African swine fever virus antibodies by indirect ELISA, and the E146L protein is used as the coating antigen.
2. The application of African swine fever virus membrane protein E146L in the preparation of positive serum detection reagents and kits for African swine fever virus diagnosis, characterized in that, The African swine fever virus membrane protein E146L is a protein composed of amino acid residues 30 to 146 of the E146L protein of the African swine fever virus Pig / HLJ / 18 strain, and its amino acid sequence is shown in SEQ ID NO.1; the diagnostic positive serum detection reagent and kit are used to detect African swine fever virus antibodies by indirect ELISA, and the E146L protein serves as the coating antigen.
3. The application of African swine fever virus membrane protein E146L in the preparation of vaccines and drugs for the prevention of African swine fever virus, characterized in that, The African swine fever virus membrane protein E146L is a protein composed of amino acid residues from position 30 to 146 of the E146L protein of the Pig / HLJ / 18 strain of African swine fever virus, and its amino acid sequence is shown in SEQ ID NO.
1.
4. The application according to claim 3, characterized in that, The vaccine is an African swine fever subunit vaccine.
5. The application of a recombinant expression plasmid containing the gene expressing the African swine fever virus membrane protein E146L in the preparation of antigen reagents and kits for African swine fever virus diagnosis, or positive serum detection reagents and kits for African swine fever virus diagnosis, characterized in that, The nucleotide sequence of the gene expressing the African swine fever virus membrane protein E146L is shown in SEQ ID NO.2, and the protein encoded by the gene is the extracellular region protein composed of amino acid residues 30 to 146 of the E146L protein of the African swine fever virus Pig / HLJ / 18 strain, the amino acid sequence of which is shown in SEQ ID NO.1; the diagnostic antigen reagent and kit or the positive serum detection reagent and kit are used to detect African swine fever virus antibodies by indirect ELISA, and the E146L protein expressed by the recombinant expression plasmid is used as the coating antigen.
6. The application of a recombinant expression plasmid containing the gene expressing the African swine fever virus membrane protein E146L in the preparation of a vaccine for the prevention of African swine fever virus, characterized in that, The nucleotide sequence of the gene expressing the African swine fever virus membrane protein E146L is shown in SEQ ID NO.2, and the protein encoded by the gene is the extracellular region protein composed of amino acid residues 30 to 146 of the E146L protein of the African swine fever virus Pig / HLJ / 18 strain, the amino acid sequence of which is shown in SEQ ID NO.1.
Citation Information
Patent Citations
Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
CN113543801A
